This research project is dedicated to the development and optimization of non-peptide ligands designed to activate insulin receptors, fundamentally transforming approaches to glycemic control in the management of diabetes. The innovative strategy at the core of this project involves designing distinct ligands for insulin receptor binding sites. This approach aims to uncover a new generation of receptor modulators that might be suitable for oral administration, addressing a long-standing challenge in diabetes therapeutics. By dissecting and specifically targeting the insulin receptor binding sites with designed ligands, the project has the potential to yield unprecedented insights and introduce transformative therapeutic options. If successful, the outcomes of this research will not only provide a novel and more convenient treatment alternative for diabetes but will also significantly improve the quality of life and health outcomes for millions of individuals living with this chronic condition.